You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1 Checkpoint Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gut and Tumor Microbiome in Advanced ER-positive and

Not yet recruiting
  • Breast Cancer
  • Melanoma
  • Observation
  • (no location specified)
Nov 6, 2023

Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer Trial in Los Angeles,

Recruiting
  • Recurrent Skin Squamous Cell Carcinoma
  • +4 more
  • Cemiplimab
  • Resection
  • Los Angeles, California
  • +2 more
Nov 12, 2022

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

Active, not recruiting
  • Recurrent Nasopharyngeal Carcinoma
  • +2 more
  • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
  • Guangzhou, Guangdong, China
    Yanqun Xiang
Sep 5, 2022

Brain Cancer Trial in United States (MK-3475)

Completed
  • Brain Cancer
  • Los Angeles, California
  • +6 more
Jun 6, 2022

NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

Not yet recruiting
  • NSCLC Associated With Leptomeningeal Metastases
  • Tislelizumab, pemetrexed
  • (no location specified)
Nov 21, 2023

Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Recruiting
  • Graft Rejection
  • +3 more
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
Jun 21, 2023

Rectal Cancer Trial in New York (Etrumadenant (AB928), Radiation therapy, FOLFOX regimen)

Recruiting
  • Rectal Cancer
  • Etrumadenant (AB928)
  • +3 more
  • New York, New York
  • +2 more
Apr 10, 2022

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Intensity Modulated Radiation Therapy
  • +3 more
  • (no location specified)
Jul 11, 2023

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)

Recruiting
  • Solid Tumors, Adult
  • NECVAX-NEO1
  • Kaunas, Lithuania
    Elona Juozaityte
May 16, 2022

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Solid Tumor, Adult Trial in Orlando, Cincinnati (ADA-011, PD(L)-1 inhibitor)

Recruiting
  • Solid Tumor, Adult
  • Orlando, Florida
  • +1 more
Jan 6, 2023

Cervical Cancer, Cervical Carcinoma Trial in Guangzhou (Zimberelimab, Lenvatinib)

Not yet recruiting
  • Cervical Cancer
  • Cervical Carcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Renal Cell Carcinoma Trial in United States (Interleukin-2, Nivolumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Ann Arbor, Michigan
  • +3 more
Jun 16, 2021

Carotid Artery Plaque, Pd-1 Inhibitors Trial in Hangzhou (PD-1 inhibitor)

Recruiting
  • Carotid Artery Plaque
  • Pd-1 Inhibitors
  • PD-1 inhibitor
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
Sep 17, 2022

Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Feb 15, 2022

Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

Recruiting
  • Classical Hodgkin Lymphoma
  • +2 more
  • Duarte, California
  • +4 more
Jun 27, 2022

Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation

Completed
  • Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
  • Anti-PD-1 or anti-PD-L1
  • Montpellier, France
    UH Montpellier
Dec 22, 2021

Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora Trial in Guangzhou (RX-af01)

Recruiting
  • Solid Tumor
  • +2 more
  • Guangzhou, Guangdong, China
    Miao-Zhen Qiu
Oct 8, 2022

Rectal Tumors Malignant, Radiotherapy Trial in Beijing, Shenzhen (drug, radiation, combination product)

Not yet recruiting
  • Rectal Neoplasms Malignant
  • Radiotherapy
  • Beijing, Beijing, China
  • +1 more
Jul 29, 2022

Gastric Cancer, Chemo Effect, Immune Checkpoint Inhibitor Trial in Shanghai (Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU)

Recruiting
  • Gastric Cancer
  • +2 more
  • Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 1, 2023

Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Immune checkpoint inhibitor
  • Ljubljana, Slovenia
    Institute of Oncology Ljubljana
May 17, 2023